Finerenone Racemate Separation Using Diastereomeric Tartaric Esters
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing enantiomerically pure finerenone (Ia) are costly due to the use of expensive chiral phases and complex chromatographic processes, which require specialized equipment and high energy consumption, making them unsuitable for large-scale production.
Innovation Solution
An optical resolution process using aromatically or heteroaromatically substituted tartaric acid esters to form diastereomeric salts, which are then converted into enantiomerically pure finerenone (Ia) using conventional pilot plant equipment, avoiding the need for expensive chromatography and specialized facilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chromatographic processes with expensive chiral phases are used, then enantiomeric purity is improved, but production cost increases
Solution Approach 1:
The patent replaces expensive, limited-lifespan chiral phases with readily commercially available chiral stationary phases that can be used repeatedly. The chiral phase mentioned (Chiralpak AS-V) is a standard commercial product that eliminates the need for custom synthesis and frequent replacement, significantly reducing both material costs and operational complexity while maintaining high enantiomeric purity (>99% e.e.) in finerenone production.
2Productivity
If chromatographic separation equipment is used, then separation efficiency is improved, but device complexity increases
Solution Approach 1:
The patent uses a conventional chromatography column with a commercially available chiral phase as a simplified copy of complex SMB systems. This approach replicates the essential separation function using standard pharmaceutical equipment that is already present in most production facilities, eliminating the need for specialized SMB infrastructure while achieving comparable or superior separation efficiency for finerenone.
3Loss of substance
If solvent recovery facilities are installed, then solvent reuse is improved, but energy consumption increases
Solution Approach 1:
The patent employs a solvent system (methanol/acetonitrile 60:40) optimized for direct evaporation and recovery using conventional equipment. The choice of solvents with appropriate boiling points and the optimized eluent composition allow for efficient solvent removal and recovery in standard falling-film evaporators without requiring excessive energy input, while still achieving high solvent reuse rates and minimizing waste.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high enantiomeric excess (>95% e.e.) of diastereomeric salts, allowing finerenone to be produced in >99% e.e. with reduced costs and using standard pharmaceutical production equipment, eliminating the need for additional capital investments and energy-intensive solvent recovery steps.
Implementation Method 1
optical resolution of the compound of formula (IV) by means of a tartaric ester of formula (IIIa) or (IIIb) to form the diastereomeric salt of formula (Va) and/or (Vc)
Data Source
AI summary
The invention relates to a diastereomeric salt of the formula (Va), (Vb), (Vc) and/or (Vd), to a process for preparing one or more of the diastereomeric salts of the formula (Va), (Vb), (Vc) and/or (Vd), to a process for preparing the compound of the formula (IVa), to a process for preparing the compound of formula (Ia), and to the use of a tartaric ester of the formula (IIIa) or (IIIb) in a process for preparing the compound of formula (Va), (Vb), (Vc), (Vd), (IVa), and/or (Ia).